Literature DB >> 10872343

Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease.

T McLaughlin1, G Reaven.   

Abstract

Essential hypertension is prevalent among older individuals, and approximately 50% of persons with hypertension can be considered to have insulin resistance and hyperinsulinemia. It appears likely that insulin resistance and hyperinsulinemia predispose to, rather than result from, hypertension. Insulin resistance is associated with abnormalities in lipoprotein metabolism, hypercoagulability, and endothelial function, which probably account in part for the increased cardiovascular risk among hypertensive patients. To identify this subset of patients, all hypertensive patients should be screened for diabetes and lipid abnormalities. The presence of impaired glucose tolerance, diabetes, or hypertriglyceridemia and low HDL suggest the presence of insulin resistance. Insulin resistant patients, in particular, will benefit from exercise and weight loss.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10872343

Source DB:  PubMed          Journal:  Geriatrics        ISSN: 0016-867X


  3 in total

1.  Clinical impact of angiotensin I converting enzyme polymorphisms in subjects with resistant hypertension.

Authors:  Egidio Imbalzano; Marco Vatrano; Sebastiano Quartuccio; Rossella Di Stefano; Caterina Oriana Aragona; Federica Mamone; Angela D'Ascola; Michele Scuruchi; Francesca Felice; Giovanni Trapani; Angela Alibrandi; Vincenzo Antonio Ciconte; Roberto Ceravolo; Antonino Saitta; Giuseppe Mandraffino
Journal:  Mol Cell Biochem       Date:  2017-02-11       Impact factor: 3.396

2.  Neuropathy associated with prediabetes: what is new in 2007?

Authors:  J Rob Singleton; A Gordon Smith
Journal:  Curr Diab Rep       Date:  2007-12       Impact factor: 4.810

3.  Polyneuropathy with Impaired Glucose Tolerance: Implications for Diagnosis and Therapy.

Authors:  J Robinson Singleton; A Gordon Smith; James Russell; Eva L Feldman
Journal:  Curr Treat Options Neurol       Date:  2005-01       Impact factor: 3.972

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.